Please assess the completion status of the following clinical trial:

Trial Title: Hyperthermic Intraoperative Intraperitoneal Chemotherapy of Recurrent Ovarian Cancer - A Feasibility Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with histologically confirmed and recurrent epithelial ovarian carcinoma, fallopian tube carcinoma or primary peritoneal carcinoma requiring secondary debulking. Last chemotherapy of primary treatment was finished at least 6 months before.~* Patient must give written informed consent before registration~* WHO/ECOG performance status 0 - 1~* Age ≥18 years, ≤70 years~* Adequate hematological values: leukocytes ≥3x10\^9/l, thrombocytes ≥100x10\^9/l~* Adequate renal function. Obstructive hydronephrosis as a cause of borderline (30 - 45 ml/min) renal function should be investigated and treated prior to study entry.~* Patient compliance and geographic proximity allow proper staging and follow-up.~* FIGO III and IV~Exclusion Criteria:~* Primary diagnosis of epithelial ovarian cancer, or primary treatment completed less than 6 months ago.~* FIGO stage I + II~* Distant and current metastases~* WHO/ECOG performance status ≥2~* Inadequate hepatic function: bilirubin \>1.5x ULN (upper limit normal range) or ASAT/ALAT \>2.5x ULN or AP \>5x ULN~* Psychiatric disorder precluding understanding of information of trial related topics or giving informed consent~* Concurrent treatment with other experimental drugs or other anti-cancer therapy, treatment in a clinical trial within 30 days prior to trial entry~* Any serious underlying medical condition (at the judgment of the investigator) which could impair the ability of the patient to participate in the trial (e.g. active autoimmune disease, uncontrolled diabetes)~* Known hypersensitivity to cisplatin~* Any concomitant drugs contraindicated for use with the trial drugs according to the Swissmedic-approved product information~* Dehydration~* Impaired hearing or symptomatic peripheral neuropathy: ≥grade II NCI-CTCAEv3~* Regular use of anti-epileptics

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- HIPEC treatment (Type: EXPERIMENTAL): Cytoreduction~Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) with cisplatin~Perfusion of the peritoneum with 42°C warm 25 mg/l cisplatin solution. Perfusion volume depends on body size (3 - 6 l).~If cisplatin amount exceeds the equivalent of 62.5 mg/m² body surface, cisplatin is dosed by body surface (62.5 mg/m²)(safety margin).~Perfusion is performed with the open or Coliseum technique for 90 min.

Based on this trial design, predict the completion outcome and termination type (if applicable).